Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

An Updated Report of the Trends in Cancer Incidence and Mortality in Japan

(2013) Kota Katanoda et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos)

(2013) Seiki Kiriyama et al.   Journal of Hepato-Biliary-Pancreatic Sciences

The prognostic and predictive value of serum CA19.9 in pancreatic cancer

(2012) J. L. Humphris et al.   ANNALS OF ONCOLOGY

Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Advanced Cholangiocarcinoma Patients Treated With Gemcitabine-Based Adjuvant Chemotherapy After Surgical Resection

(2012) Hironori Kobayashi et al.   ANNALS OF SURGERY

CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy

(2012) Werner Hartwig et al.   ANNALS OF SURGICAL ONCOLOGY

Surgical Resection after Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer: A Retrospective Single-center Study

(2012) Atsushi Kato et al.   ANNALS OF SURGICAL ONCOLOGY

Preoperative Serum CA 19-9 Level as a Predictive Factor for Recurrence after Curative Resection in Biliary Tract Cancer

(2011) Moon Jae Chung et al.   ANNALS OF SURGICAL ONCOLOGY

Survival Analysis of Intrahepatic Cholangiocarcinoma After Resection

(2010) Seong Yeon Cho et al.   ANNALS OF SURGICAL ONCOLOGY

Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma

(2010) Yoshiaki Murakami et al.   ANNALS OF SURGICAL ONCOLOGY

Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer

(2010) Naru Kondo et al.   ANNALS OF SURGICAL ONCOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies

(2010) Ioannis Hatzaras et al.   HPB

Adjuvant Gemcitabine Plus S-1 Chemotherapy Improves Survival After Aggressive Surgical Resection for Advanced Biliary Carcinoma

(2009) Yoshiaki Murakami et al.   ANNALS OF SURGERY

Preoperative Serum CA19-9 and Dissected Peripancreatic Tissue Margin as Determiners of Long-Term Survival in Pancreatic Cancer

(2009) Mina Waraya et al.   ANNALS OF SURGICAL ONCOLOGY

Gemcitabine-Based Adjuvant Chemotherapy Improves Survival After Aggressive Surgery for Hilar Cholangiocarcinoma

(2009) Yoshiaki Murakami et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma

(2009) Joshua G. Barton et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience

(2009) Tsuyoshi Igami et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma

(2009) Seung-Mo Hong et al.   SURGERY

Smoking and serum CA19-9 levels according toLewisandsecretorgenotypes

(2008) Sayo Kawai et al.   INTERNATIONAL JOURNAL OF CANCER

Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704

(2008) Adam C. Berger et al.   JOURNAL OF CLINICAL ONCOLOGY